RSA 키 (2048)

-----BEGIN PRIVATE KEY----- MIIEvgIBADANBgkqhkiG9w0BAQEFAASCBKgwggSkAgEAAoIBAQCk27mhBKOIRQLB OHTtrX3rlGGzrn4OljeNHLBhzl5V1y85W9DiDVEVR0hRWOxcMHmlFj2TlK7EVd3r Gi2Fg2u/1IGpB2eIsucWu2KoB6ieP7ZUJeO9k0uMpx+oukTRa0JpIs7vp4vasf7X 5P8liIUQe9fHNs/tTsjJzkzszcp/Dn0+O593ShSx1hGaGcRT8Q01FQlY5QvCro8U Emdlul3RJ6zDkYCNCmuDrpMdFPpS6rfzUG3HdmjmyZOAYIP591NwjLEFHsSRLunI 7tA486MWojdd+44LSjkScfBqLpS2cE3TWGA/lFy/6VFI8X0R1cluzSaJW4+s/Urk GHfntU3VAgMBAAECggEACkab4np8iwDqNAsF1s7Km4WLNXz55ITef5A7Ok13udgI 3IVplr2HwVDJJDDrwq9O1ch2HB3XauuDQqVGEx1m+PURA+0vOekU2GjjtF+N1hdY kRQvhuCIhALiyUya/4a1BAKkbXG/GOmhXemrMba5vJZLk+JJwZv4jgOq7dPB/Htc HNfa2wP6QNzgiNPfDr51ScX5arjfVV2GEvGayDdzRrxTNYFySyUsdHI37ax9RL08 8TUsIgbJ9HUrWc/9cLW0w6BfoLbkgpjyJDKVzNbfmjHmT/VocIihEhblZo4AjC3p Y9seOuluDg+GlwptndQJ6P2zXa5pyK5ZC5KlBG2vQQKBgQDOAVlE87UbrgNSKLie TDidlVEmNhvnAfXODxQm7orVqzcxqBk3vse5HsQaY3//abF4wEEpwHpVo14u5zKC HlPOd4naW8+A0LTafhxV5Q6/rFPG7/MaHNi+hPZdlMPPXSuUoTuniE+LE9oGS7VO Y5NP7Krhtf0hsvQOkdftklJNBQKBgQDM3gGk2MIzzsw0lqRGA92InT30Az7Uxe6f BiQu7f192+PzYN2Bm9iP0zuKd4DeAbH3Sn2KZC1ld/2MJKhx/Yh6zLIrIfnld9DP HGbwbkxDazcIOKg7aIRN0zwPU8s2A9KhpaQEWsquO9jbJ0jM1uPssNiceYQwfkIH v2CG4dhWkQKBgQDBaorCLn8wieUcUpdkKPRPIE6crdjsv+5llcq58uXvT133BXkH 2dvzd2tvy1P2Huo+EWQdK1aw6T4Yk4HcoVTWWW3Y0rK0oz/qlNVN4E5EsCvIcKmz Lrphxrz5iB+Apl2wouE7nsPwNKdTmemUu/En7XFTkmckKLz0oQI3UFZtcQKBgQCL 6AEPZsgZQVzLfSTqe7FKnre0cJL0E8gF6dfEBNtcnFJr3vbmkFuwvPyobzweYOH8 k25wmEE4Tl1k25P9ZLtTwX7bXfSe9Ngw2KCkCW8ji5ClmKurBpFz5JHblcntNWce 5VPBdY98tXo/D/Dzkr1M4ujK02GnDFJjoBp3gryPQQKBgDjRuqbkI76M/Koq337T BMomdjJdadsXSu98cU3V8L3r3GSR9Sjg6C0KjnEd+l/yGPc9lyoReir6j27pMM4H +z5zuQsF/F6G1u89n/C6FoBjGhcVzAdssT/sGfVWsdzKU6LElgmxKpTMqyKUtA5v qzPLOyu9i63oK8DI2CRlrztn -----END PRIVATE KEY-----


-----BEGIN PUBLIC KEY----- MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApNu5oQSjiEUCwTh07a19 65Rhs65+DpY3jRywYc5eVdcvOVvQ4g1RFUdIUVjsXDB5pRY9k5SuxFXd6xothYNr v9SBqQdniLLnFrtiqAeonj+2VCXjvZNLjKcfqLpE0WtCaSLO76eL2rH+1+T/JYiF EHvXxzbP7U7Iyc5M7M3Kfw59Pjufd0oUsdYRmhnEU/ENNRUJWOULwq6PFBJnZbpd 0Sesw5GAjQprg66THRT6Uuq381Btx3Zo5smTgGCD+fdTcIyxBR7EkS7pyO7QOPOj FqI3XfuOC0o5EnHwai6UtnBN01hgP5Rcv+lRSPF9EdXJbs0miVuPrP1K5Bh357VN 1QIDAQAB -----END PUBLIC KEY-----

자유게시판

CS Center

tel. 02-715-4734

am 10:00 ~ pm 6:00

공휴일 휴관
(사전예약 후 관람가능)

010-5217-9505
orbgallery@naver.com

The Background of Flibanserin: From Development to FDA Authorization

페이지 정보

profile_image
작성자 Claude
댓글 0건 조회 20회 작성일 24-04-07 23:12

본문

2 years later on, in 2015, alldaychemist.com the FDA ultimately granted authorization for Flibanserin, noting it as the very first drug accepted to deal with HSDD in premenopausal females. Because its authorization, globalcargo.com.pk Flibanserin has been a game-changer for ladies's health, specifically in the location of sex-related health and wellness. While Flibanserin may not have started as a medicine planned to treat HSDD, its journey and eventual FDA approval have actually had a significant effect on ladies's health.


Instead of treating anxiety, the business determined to explore Flibanserin's possible to take on HSDD. Flibanserin first looked for authorization from the FDA in 2010. Two years later, in 2015, the FDA lastly granted authorization for Flibanserin, marking it as the very first medicine approved to treat HSDD in premenopausal females. Because its approval, Flibanserin has been a game-changer for females's health, particularly in the area of sexual health. While Flibanserin might not have started as a medication meant to deal with HSDD, its trip and ultimate FDA approval have had a substantial impact on females's health.

댓글목록

등록된 댓글이 없습니다.